Caplin Point Laboratories has announced its financial performance for the second quarter of FY25, showcasing notable growth in revenue from operations and net profit year-over-year (YoY).
Financial Highlights
- Revenue from Operations: The company reported revenue from operations of ₹483.10 crore for Q2 FY25, reflecting a 17.8% increase from ₹410.06 crore in Q2 FY24. On a quarter-over-quarter (QoQ) basis, revenue saw a 5.3% increase from ₹458.96 crore in Q1 FY25.
- Profit Before Tax (PBT): The PBT for Q2 FY25 stood at ₹168.46 crore, marking a 15.4% YoY increase from ₹146.00 crore in Q2 FY24. QoQ, PBT rose by 9.1% from ₹154.38 crore in Q1 FY25.
- Net Profit: Caplin Point recorded a net profit of ₹130.81 crore in Q2 FY25, up 12.7% YoY from ₹116.14 crore in Q2 FY24. Compared to the previous quarter, net profit grew by 4.7% from ₹124.92 crore in Q1 FY25.
Caplin Point’s consistent revenue growth and profitability underscore its strong operational performance, driven by efficient cost management and expanding market reach.
Summary
Caplin Point Laboratories continues to deliver steady growth, with impressive improvements in its revenue from operations and net profit. The company’s focus on expanding its market presence and optimizing operations positions it for sustained success in the pharmaceutical industry.
